UiPath Inc. (PATH) woke up on the right side of the bed Thursday, with shares jumping 8.7% to $16.18 in premarket trading. The automation software company delivered exactly what Wall Street loves: a solid earnings beat paired with guidance that suggests the good times aren't over yet.
The numbers tell a straightforward story. UiPath reported adjusted earnings of 16 cents per share for the third quarter, edging past analyst expectations of 15 cents. More impressively, revenue hit $411.11 million, comfortably ahead of the $392.97 million consensus estimate and representing healthy growth from the $354.65 million the company brought in during the same quarter last year. The company's fourth-quarter sales guidance came in with a midpoint above what analysts were expecting, giving investors another reason to bid up the stock.
But UiPath wasn't the only name making waves before the opening bell. The premarket session delivered its usual mix of dramatic moves, particularly among biotech and healthcare companies where news can send stocks on wild rides in both directions.
The Big Winners
Polyrizon Ltd (PLRZ) absolutely exploded, gaining 158.1% to $18.30. The Israel-based biotechnology company released preclinical test data Wednesday showing its proprietary naloxone hydrogel sticks to nasal tissue longer than an approved intranasal naloxone spray currently available. For a company developing opioid overdose treatments, that's the kind of data that can change everything.
Robotics got some unexpected attention as Nauticus Robotics, Inc. (KITT) surged 34% to $2.09. The catalyst? Reports that Commerce Secretary Howard Lutnick has been sitting down with robotics industry CEOs and backing efforts to accelerate sector growth. Sometimes all it takes is the right person showing interest in your industry.
Picard Medical, Inc. (PMI) climbed 22.3% to $2.47, though the company didn't announce any specific catalyst for the move.
Meiwu Technology Company Limited (WNW) gained 20.9% to $1.68 after announcing a memorandum of understanding with Real BioTech (Qingdao) Ltd. MOUs are non-binding agreements, but they signal potential future partnerships that investors sometimes get excited about.
Universe Pharmaceuticals INC (UPC) added 19.5% to $4.22 in early trading without any apparent news driving the move.
Hyster-Yale, Inc. (HY) rose 13.6% to $39.03, continuing momentum after gaining more than 15% on Wednesday. When a stock starts moving, sometimes it just keeps going.
KALA BIO, Inc. (KALA) climbed 13.5% to $1.05 after Securities and Exchange Commission filings revealed that Oxford Finance LLC acquired 1.62 million common shares, representing 16.5% ownership in the clinical-stage company. Big institutional buyers stepping in can provide validation that moves share prices.
Axogen, Inc. (AXGN) jumped 11% to $31.43 following some genuinely significant news: the FDA approved its Biologics License Application for AVANCE (acellular nerve allograft-arwx). FDA approvals are the holy grail for biotech companies, transforming experimental products into commercial realities.
Anbio Biotechnology (NNNN) shares rose 9.7% to $37.88, building on Wednesday's 25% gain. Whatever sparked that initial move clearly has staying power.
The Strugglers
Not everyone enjoyed a pleasant morning. Virax Biolabs Group Ltd (VRAX) tumbled 16.2% to $0.58 after the London-based biotechnology company announced definitive agreements to sell 12.5 million ordinary shares at $0.40 per share in a private placement. Dilution is rarely popular with existing shareholders, especially when the offering price sits well below recent trading levels.
Treasure Global Inc (TGL) declined 13.3% to $0.26, extending Wednesday's brutal 35% decline. The company announced a 1-for-20 reverse stock split and received a Nasdaq delisting notification—neither of which inspires confidence in near-term prospects.
Net Lease Office Properties (NLOP) fell 14.7% to $25.19 without any obvious catalyst for the decline.
Addex Therapeutics Ltd - ADR (ADXN) dipped 11.4% to $7.84 after reporting a third-quarter loss of $1.50 per share. Sometimes earnings reports don't go the way you'd hoped.
Vicarious Surgical Inc (RBOT) shares slipped 11.1% to $2.93 despite gaining 27% on Wednesday. The company lowered its full year 2025 cash burn outlook, which you'd think would be good news (burning less cash is generally preferable to burning more). But coming off a big rally, any excuse for profit-taking can trigger selling.
Symbotic Inc (SYM) fell 10.5% to $65.50 after announcing a 10 million share offering, including 6.5 million shares from the company and 3.5 million from a selling stockholder. More dilution, more selling pressure.
Immuron Ltd - ADR (IMRN) dropped 9.1% to $1.41, adding to Wednesday's 11% decline.
Snowflake Inc (SNOW) fell 8.6% to $241.85 after posting quarterly results. The cloud data company has been a high-flyer, and expectations tend to run sky-high for such names. Meeting expectations sometimes isn't enough when investors want you to exceed them.
Capricor Therapeutics Inc (CAPR) dipped 8.4% to $27.45 after absolutely exploding 371% on Wednesday. The company announced topline results from its Phase 3 HOPE-3 Trial evaluating deramiocel cell therapy for Duchenne Muscular Dystrophy, which met its primary endpoint and secondary cardiac endpoint. That's objectively fantastic news, but after nearly quintupling in a single session, some profit-taking is almost inevitable.
Koninklijke Philips NV (PHG) fell 6.8% to $26.11 in early trading.
Premarket trading offers a preview of market sentiment before the real action begins. With earnings season in full swing and biotech news flowing, expect more volatile mornings ahead.
